Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 antigen tests for screening of healthcare workers; experience with over 48,000 combined antigen tests and RT-PCR tests

A. Piek *, M. Knoester, L. Gard, M. Lokate, H.G.M. Niesters, C.L. van Leer-Buter

University of Groningen, University Medical Center Groningen, Department of Medical Microbiology and Infection Prevention, Division of Clinical Virology, Groningen, the Netherlands

ARTICLE INFO

Keywords:
SARS-CoV-2
Antigen test
Hospital management
Infection prevention
Real-time polymerase chain reaction
Health care worker

ABSTRACT

Background: To prevent spread to patients and co-workers, health care workers (HCWs) infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) should quickly be identified. Although real-time polymerase chain reaction (RT-PCR) is the gold standard, this test takes several hours, during which a HCW is unable to work. Antigen (Ag) tests may be an efficacious means of screening HCWs since they are easy to perform and provide fast results.

Methods: In this study, 48,010 paired results of Ag-testing and RT-PCR, performed on HCWs between January 2021 and April 2022, were evaluated to determine the diagnostic accuracy of SARS-CoV-2 Ag-tests in diagnosing potentially infectious individuals. This analysis was performed with cycling threshold values (Ct-values) ≤ 30 and ≤ 25 as cut-offs.

Results: Respectively 3.1% (n = 1507) and 0.3% (n = 140) of Ag-tests were positive or indeterminate, and thus indicative for SARS-CoV-2 infection. In total, 2479 (5.2%) RT-PCRs were positive, of which 1529 (61.7%) had a Ct-value ≤ 25 and 402 (16.2%) a Ct-value between 26 and 30. At Ct-value ≤ 30 as a cut-off, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Ag-tests were 79.0%, 99.8%, 93.8% and 99.1%, respectively. At Ct-value ≤ 25, sensitivity further improved to 92.0%, by which the NPV increased to 99.7%.

Conclusions: To prevent transmission from HCWs to patients and co-workers, while maintaining workforce capacity, Ag-tests are a valuable addition to RT-PCR tests, as they have a quick turnaround time and excellent sensitivity for identifying individuals with high potential for transmission.

Background

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a major pandemic affecting millions around the globe, and till date the spread of SARS-CoV-2 is ongoing [1,2]. Coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, is mainly characterized by respiratory symptoms, but can also include non-respiratory symptoms [3,4]. In severe cases, COVID-19 can lead to respiratory failure, multiorgan disease and death [3,4].

With respect to infection control, it is advised that an infected person completes an isolation period to prevent spreading of the virus to others [1,2,5,6]. Especially in a medical/hospital setting, identifying infectious health care workers (HCWs) is important to prevent spread amongst co-workers and patients. Thus, fast and reliable diagnostic methods are necessary.

The most used technique in the medical setting for SARS-CoV-2 diagnostics is real-time polymerase chain reaction (RT-PCR) [7]. RT-PCR is relatively expensive, time consuming and not universally available. SARS-CoV-2 antigen (Ag) tests are an interesting diagnostic method to screen HCWs since they are relatively cheap, easily manually performed,
and provide fast results, potentially allowing the identification of infectious individuals within minutes [8–11]. Several studies showed that SARS-CoV-2 Ag-tests have high specificity but varying sensitivity [8–11].

Here, we aimed to determine the value of SARS-CoV-2 Ag-tests in HCW testing. Therefore, 48,010 paired results of Ag-testing and RT-PCR, performed on HCWs between January 2021 and April 2022, were evaluated to determine the diagnostic accuracy of SARS-CoV-2 Ag-tests in diagnosing potentially infectious individuals.

Methods

Study design

In the University Medical Center Groningen (UMCG), a large tertiary referring center employing >14,000 HCWs, HCWs at risk for a SARS-CoV-2 infection (i.e. having signs/symptoms of a SARS-CoV-2 infection, having a recent close contact with a person positively tested for SARS-CoV-2, or traveling to a region/country with a high infection rate [6]) were tested for SARS-CoV-2 with RT-PCR. HCWs planning to work in the hospital with proper personal protection equipment (PPE) awaiting the UMCG (instead of at home) were also tested with a SARS-CoV-2 Ag-test. Following a negative Ag-test result, HCWs were allowed to work in the hospital. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used for RT-PCR. HCWs planning to work in the hospital with proper personal protection equipment (PPE) awaiting the RT-PCR result. The RT-PCR result would follow within eight hours after sample collection. All HCWs of the UMCG, including non-medical staff, were included in this testing regimen, which is summarized in Fig. 1.

Sample collection and testing

Respiratory samples were collected by nasopharyngeal swabbing followed by oropharyngeal swabbing, using a nasopharyngeal flocked swab. Swabbing was performed by trained employees. This procedure was done twice. One sample was immediately processed for the SARS-CoV-2 Ag-test. A second sample was collected in 3 ml Universal Transport Medium (Copan, USA) and stored at room temperature until performance of the RT-PCR.

From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used. From January-October 2021 and January-April 2022, the Panbio SARS-CoV-2 Ag-test (COVID-19 Ag Rapid Test Device, Abbott, USA) was used. Ag-tests were used. From October 2021 until January 2022 the Biosynex SARS-CoV-2 Ag-test (COVID-19 Ag BSS, Biosynex, France) was used. Ag-tests were used.

Population characteristics

From January 2021 until April 2022, a total of 10,381 individual HCWs were screened once or multiple times for SARS-CoV-2 infection by Ag-test and RT-PCR (Fig. 1, Supplemental Table 1). In total, 48,010 combined tests were performed. The majority of tests were performed in male HCWs (n = 7634, 73.5%). The median age of the population was 35.2 years (IQR 26.8–48.9 years). The median number of combined tests per individual was 3 (IQR 1–6 screenings) (Fig. 2A, Supplemental Table 1). The Alpha variant was dominant until week 23 of 2021, the Delta variant from week 24 until week 51 of 2021, and the Omicron variant (BA.1 or BA.2) from week 52 of 2021 and onwards (data not shown). During the dominance of the respective variants, 15,862, 14,909 and 17,239 paired tests were performed.

Ag-tests were performed with the Biosynex kit and Panbio kit in respectively 13,269 (27.6%) and 34,741 (72.4%) of screenings (Supplemental Table 2). Only Panbio Ag-tests were used during the dominance of the Alpha variant, whilst both types were used during the dominance of the Delta and the Omicron variant (Fig. 2B). Overall, 1507 (3.1%) Ag-tests showed a positive and 140 (0.3%) an indeterminate result (Fig. 2C, Supplemental Table 2).

Most RT-PCR tests were performed on the Alinity-M system (n = 34,679; 72.2%) and lab developed RT-PCR (n = 13,288; 27.7%) (Supplemental Table 1). In total, 2479 (5.2%) RT-PCRs had a positive result, of which 1529 (61.7%) had a Ct-value ≤25 and 402 (16.2%) a Ct-value between 26 and 30 (Fig. 2D, Supplemental Table 2).

Diagnostic accuracy of SARS-CoV-2 Ag-tests

Next, the overall diagnostic accuracy of SARS-CoV-2 Ag-tests was determined in the entire testing population. The classification of Ag-test results with RT-PCR as the reference standard is shown in Table 1. In 97.8% of screenings, the Ag-test resulted in a correct classification, and a sensitivity of 62.3% and a specificity of 99.8% was observed (Table 2).
**Fig. 1. Schematic overview of health care worker testing regime.** Health care worker (HCW) screening was divided into five different phases. Phase 1 ($T = 0 \text{ min}$) was generally performed by the health care worker himself/herself. Indication for testing was based on (1) signs and/or symptoms of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, (2) close contact with a known positive person, or (3) after travelling to endemic areas as defined by the European Center of Disease Prevention and Control (ECDC) [2,5,6]. In phase 2 ($T = 0 \text{ min}$), the test regime was determined. Asymptomatic or mild-symptomatic individuals planning to go to work in the University Medical Center Groningen (UMCG) (instead of at home) on the day of testing were tested with both a SARS-CoV-2 antigen (Ag) test and a SARS-CoV-2 Real-time polymerase chain reaction (RT-PCR). Otherwise, only SARS-CoV-2 RT-PCR was performed. In phase 3 ($T = 15–30 \text{ min}$), based on the Ag-test result, it was decided whether a HCW was allowed to work at location awaiting the RT-PCR result (i.e. when the Ag-test result was negative), or should await the PCR result at home (when the Ag-test result was indeterminate (IND) or positive). In phase 4 ($T \leq 8 \text{ h}$), based on the RT-PCR result, the final decision was made on whether a HCW was allowed to work at location or should go into isolation.
The PPV was 93.9% and the NPV was 98.0%. In total, 140 Ag-tests were classified as indeterminate. Of these, 77 (55.0%) had a negative, and 63 (45.0%) a positive or indeterminate RT-PCR result.

Looking into HCWs with false negative Ag-tests, the median Ct-value in RT-PCR was significantly higher as compared to HCWs with a true positive result (Ct-value 31 (IQR 28–34) vs. 19 (17–22), P<0.001). This can also be seen in the frequency distribution of Ct-values (Fig. 3A). Taking different Ct-values as cut-off for positivity, sensitivity increased with decreasing Ct-value (i.e. with increasing viral load), whilst specificity remained stable (Fig. 3B).

By comparing the AUCs (Table 2), the diagnostic performance of Ag-tests during different variants of SARS-CoV-2 was compared. A better performance in detecting Delta variants (P = 0.013) and Omicron variants (P<0.001) was observed as compared to detecting Alpha variants, but was similar during the dominancy of the Delta and Omicron variants (P = 0.192). No significant difference in performance was observed between Biosynex and Panbio Ag-tests, and this holds true for both Ct-value cut-off ≤25 (P = 0.384) and ≤25 (P = 0.973). Also during Alpha variant dominancy, Delta variant dominancy and Omicron variant dominancy, no significant differences in diagnostic performance were observed, and this holds true both with Ct-value cut-off ≤30 (P ≥ 0.730) and ≤25 (P ≥ 0.117).

Diagnostic accuracy of SARS-CoV-2 Ag-tests for identification of infectious cases

Next, we determined the diagnostic accuracy of SARS-CoV-2 Ag-tests to identify infectious HCWs, with a Ct-value of ≤30 and ≤25 as cut-offs for infectiousness. The classification of Ag-test results with RT-PCR as the reference standard is shown in Table 1. With a cut-off at Ct-value ≤30, 98.9% of Ag-tests resulted in a correct classification (Table 2), and Ag-test sensitivity and specificity was 79.0% and 99.8%, respectively. With Ct-value ≤25 as a cut-off, 99.5% of antigen tests resulted in a correct classification. Sensitivity was 92.0%, by which the NPV increased to 99.7%. With respectively a Ct-value of ≤30 and ≤25 as cut-offs for infectiousness, 405 (0.9%) out of 47,209 Ag-tests and 122 (0.3%) out of 46,807 Ag-tests were false negative (Table 1).

No significant difference in performance (AUC, Table 2) was observed between Biosynex and Panbio Ag-tests, and this holds true for both Ct-value cut-off ≤30 (P = 0.384) and ≤25 (P = 0.973). Also during Alpha variant dominancy, Delta variant dominancy and Omicron variant dominancy, no significant differences in diagnostic performance were observed, and this holds true both with Ct-value cut-off ≤30 (P ≥ 0.730) and ≤25 (P ≥ 0.069).

Discussion

In this study, we investigated the diagnostic accuracy of SARS-CoV-2 Ag-tests as a screening method for HCWs using 48,010 paired SARS-CoV-2 Ag-tests and RT-PCRs. Ag-tests showed a good diagnostic accuracy to classify HCWs as potentially infectious or not. With lower Ct-values as cut-off for infectiousness, diagnostic accuracy was higher and this was especially true for sensitivity. Together, Ag-tests show a high sensitivity to identify individuals with a high potential for transmission, with the major advantage of providing fast results.
Table 1

Ag-test results as compared to RT-PCR as the reference standard.

| Reference standard for Ag-tests | Total no. of tests, n | Ag-test result as compared to RT-PCR reference standard, n (%) |
|---------------------------------|-----------------------|---------------------------------------------------------------|
|                                 | True negative | False negative | True positive | False positive |
| All RT-PCR results              |              |                |               |                |
| Total                            | 47,757       | 45,177 (94.6%) | 934 (2.0%)    | 1545 (3.2%)    |
| Ag-test type                     |              |                |               |                |
| Biosynex                         | 13,229       | 12,867 (97.3%) | 135 (1.0%)    | 196 (1.5%)     |
| Panbio                           | 34,528       | 32,310 (93.6%) | 799 (2.3%)    | 1349 (3.9%)    |
| Variant                          |              |                |               |                |
| Alpha                            | 15,817       | 15,543 (98.3%) | 126 (0.8%)    | 122 (0.8%)     |
| Delta                            | 14,857       | 14,555 (98.0%) | 109 (0.7%)    | 164 (1.1%)     |
| Omicron                          | 17,083       | 15,079 (88.3%) | 699 (4.1%)    | 1259 (7.4%)    |
| RT-PCR with Ct ≤30 and negatives |              |                |               |                |
| Total                            | 47,209       | 45,177 (95.7%) | 405 (0.9%)    | 1526 (3.2%)    |
| Ag-test type                     |              |                |               |                |
| Biosynex                         | 13,149       | 12,867 (97.9%) | 58 (0.4%)     | 193 (1.5%)     |
| Panbio                           | 34,060       | 32,310 (94.9%) | 347 (1.0%)    | 1333 (3.9%)    |
| Variant                          |              |                |               |                |
| Alpha                            | 15,720       | 15,543 (98.9%) | 31 (0.2%)     | 120 (0.8%)     |
| Delta                            | 14,793       | 14,555 (98.4%) | 46 (0.3%)     | 163 (1.1%)     |
| Omicron                          | 16,696       | 15,079 (90.3%) | 328 (2.0%)    | 1243 (7.4%)    |
| RT-PCR with Ct ≤25 and negatives |              |                |               |                |
| Total                            | 46,807       | 45,177 (96.5%) | 122 (0.3%)    | 1407 (3.0%)    |
| Ag-test type                     |              |                |               |                |
| Biosynex                         | 13,088       | 12,867 (98.3%) | 15 (0.1%)     | 175 (1.3%)     |
| Panbio                           | 33,719       | 32,310 (95.8%) | 107 (0.3%)    | 1232 (3.7%)    |
| Variant                          |              |                |               |                |
| Alpha                            | 15,687       | 15,543 (99.1%) | 26 (0.2%)     | 112 (0.7%)     |
| Delta                            | 14,751       | 14,555 (98.7%) | 18 (0.1%)     | 149 (1.0%)     |
| Omicron                          | 16,369       | 15,079 (92.1%) | 46 (0.3%)     | 1146 (7.0%)    |

Ag-test results are represented as true negative, false negative, true positive or false positive as compared to PCR result as reference standard. Ag = Antigen. Ct = Cycle threshold value. RT-PCR = Real time polymerase chain reaction. SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2.

Table 2

Diagnostic accuracy of SARS-CoV-2 Ag-tests.

| Reference standard for Ag-tests | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | CC (%) | AUC (95% CI) |
|---------------------------------|-----------------|-----------------|---------|---------|-------|--------------|
| All RT-PCR results              |                 |                 |         |         |       |              |
| Total                            | 62.3            | 99.8            | 93.9    | 98.0    | 97.8  | 0.811 (0.801–0.820) |
| Ag-test type                     |                 |                 |         |         |       |              |
| Biosynex                         | 59.2            | 99.8            | 86.3    | 99.0    | 98.8  | 0.795 (0.768–0.821) |
| Panbio                           | 62.8            | 99.8            | 95.1    | 97.6    | 97.5  | 0.813 (0.803–0.823) |
| Variant                          |                 |                 |         |         |       |              |
| Alpha                            | 49.2            | 99.8            | 82.4    | 99.2    | 99.0  | 0.745 (0.714–0.776) |
| Delta                            | 60.1            | 99.8            | 85.0    | 99.3    | 99.1  | 0.799 (0.770–0.828) |
| Omicron                          | 64.3            | 99.7            | 96.5    | 95.6    | 95.6  | 0.820 (0.809–0.831) |
| RT-PCR with Ct ≤30 and negatives |                 |                 |         |         |       |              |
| Total                            | 79.0            | 99.8            | 93.8    | 99.1    | 98.9  | 0.894 (0.885–0.903) |
| Ag-test type                     |                 |                 |         |         |       |              |
| Biosynex                         | 76.9            | 99.8            | 86.2    | 99.6    | 99.3  | 0.883 (0.857–0.909) |
| Panbio                           | 79.4            | 99.8            | 95.0    | 98.9    | 98.8  | 0.896 (0.886–0.905) |
| Variant                          |                 |                 |         |         |       |              |
| Alpha                            | 79.5            | 99.8            | 82.2    | 99.8    | 99.6  | 0.897 (0.864–0.929) |
| Delta                            | 78.0            | 99.8            | 84.9    | 99.7    | 99.5  | 0.889 (0.861–0.917) |
| Omicron                          | 79.1            | 99.7            | 96.4    | 97.9    | 97.8  | 0.894 (0.884–0.904) |
| RT-PCR with Ct ≤25 and negatives |                 |                 |         |         |       |              |
| Total                            | 92.0            | 99.8            | 93.3    | 99.7    | 99.5  | 0.959 (0.952–0.966) |
| Ag-test type                     |                 |                 |         |         |       |              |
| Biosynex                         | 92.1            | 99.8            | 85.0    | 99.9    | 99.7  | 0.959 (0.940–0.979) |
| Panbio                           | 92.0            | 99.8            | 94.6    | 99.7    | 99.5  | 0.959 (0.952–0.966) |
| Variant                          |                 |                 |         |         |       |              |
| Alpha                            | 94.9            | 99.8            | 81.2    | 99.8    | 99.8  | 0.974 (0.954–0.994) |
| Delta                            | 89.2            | 99.8            | 83.7    | 99.9    | 99.7  | 0.945 (0.922–0.969) |
| Omicron                          | 92.1            | 99.7            | 96.1    | 99.4    | 99.1  | 0.959 (0.952–0.967) |

AUC = Area under the receiver operating characteristics curve. Ag = Antigen. CI = Confidence interval. CC = Correctly classified. Ct = Cycle threshold value. NPV = Negative predictive value. PPV = Positive predictive value. RT-PCR = Real time polymerase chain reaction. SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2. PPV was calculated as follows: number of true positive results / (number of true positive results + number of false positive results). NPV was calculated as follows: number of true negative results / (number of true negative + number of false negative results). 95% confidence intervals (CI) for PPV and NPV are ≤0.60% and ≥0.03%. 95% CI for sensitivity and specificity are ≤0.84% and ≥0.01%.
Amongst the included HCWs, Ag-tests correctly identified 45,177 HCWs without SARS-CoV-2, who consequently were all able to work on the day of testing. Thus, during the study period the loss of 45,177 working days was prevented. Since Ag-tests are relatively cheap (approximately 5 Euros) as compared to the costs of a lost working day, including Ag-tests in the testing of HCWs for SARS-CoV-2 is likely to be highly cost-effective, both benefiting health care continuity and hospital finances.

Unfortunately, also false negative Ag-tests were observed amongst the tested HCWs and thus some HCWs were allowed to enter the work floor whilst they had the potential to be infectious for patients and co-workers. Depending on the Ct-value that is considered the cut-off for infectiousness, in our study the false negative rate of Ag-tests was 0.9% (Ct-value \( \leq 30 \)) or 0.3% (Ct-value \( \leq 25 \)). We believe that this rate is relatively low and thus acceptable, especially since our protocol prescribed that all HCWs had to wear proper PPE awaiting the RT-PCR result, which followed the Ag-test result within eight hours. By this we limited any unwanted spread of SARS-CoV-2 from HCWs with, in hindsight, a false negative Ag-test result.

Previously, several studies reported the diagnostic accuracy of SARS-CoV-2 Ag-tests [8–11]. Our study included a large amount of Ag-tests and, to our knowledge, this is the largest study till date in which all Ag-tests were confirmed by RT-PCR. The size of the dataset provides the opportunity to draw solid conclusions on SARS-CoV-2 Ag-test performance in the context of HCWs screening. Importantly, we did not observe significant differences in Ag-test performance to detect infectious cases, neither between SARS-CoV-2 variants, nor between the two used types of Ag-tests (Bioxynex and Panbio). Moreover, we observed that Ag-test sensitivity was positively associated with viral load, and this was in accordance with previous data [10,17].

Our study suggests that Ag-tests could be considered to test HCWs at risk for SARS-CoV-2 infectiousness. Importantly, we believe that several precautions are important: (1) In our center we used trained employees for sample collection Ag-test performance. This is important for a reliable performance and interpretation of Ag-tests, and especially for the interpretation of ‘weak positive’ Ag-test results [18]. (2) We used a combined nasopharyngeal and oropharyngeal swab, as with nasopharyngeal swab alone some positive HCWs might be missed. (3) Additional RT-PCR for positive Ag-test results should be considered. During low community prevalence of the virus, RT-PCR can be of value to prevent unnecessary isolation due to false positive results. (4) For early detection of SARS-CoV-2 infection, RT-PCR and/or repetitive Ag-testing should be considered, as in the early phase of SARS-CoV-2 infection viral load might be low resulting in limited Ag-test sensitivity. (5) With indeterminate Ag-test results it is important to either repeat the Ag-test and/or perform additional RT-PCR, to provide a final verdict on HCW infectiousness. Together, we think an optimal SARS-CoV-2 screening regime should entail both Ag-testing and the option for additional RT-PCR. Since amongst patients it is also important to be able to identify patients with higher Ct-values (infected but less/not infectious), we believe SARS-CoV-2 RT-PCR should remain the gold standard for patients.

Besides SARS-CoV-2 Ag-tests and RT-PCR, a wide variety of other SARS-CoV-2 testing modalities are available, all with varying diagnostic performance, turnaround time and costs. Depending on, amongst others, the size of the testing population and the locally available testing and laboratory infrastructure, other rapid detection methods, for example reverse transcriptase loop-mediated isothermal Amplification (RT-LAMP) [19–21], can be considered to be part of a SARS-CoV-2 testing regime.

Some limitations should be mentioned. First, no clinical data on signs/symptoms of positive HCWs were available. However, every Ag-test was paired with a RT-PCR result with Ct-value, providing data on the SARS-CoV-2 status and degree of infectiousness of HCWs. Second, only HCWs planning to work in the hospital (instead of at home) were also tested with an Ag-test. Since these HCWs were feeling fit enough for work, it is likely that this group had relatively minor or no signs/symptoms, and thus might have had a relatively low viral load. Possibly, this has affected the diagnostic accuracy as presented in this study, most likely resulting in an underestimate of Ag-test sensitivity, since previous studies showed a lower sensitivity of the Ag-test in asymptomatic individuals [22–24].

**Conclusion**

In conclusion, to prevent transmission from HCWs to patients and co-workers while maintaining workforce capacity, Ag-tests are a valuable addition to RT-PCR tests, as they have a quick turnaround time and excellent sensitivity for identifying individuals with high potential for transmission. By including Ag-tests in a testing regime to screen HCWs who possibly are infectious for SARS-CoV-2, and allowing HCWs with a negative Ag-test result to work awaiting the RT-PCR result, the loss of a large number of working days can be prevented, with a major impact on both health care continuity and hospital finances.

**Ethics approval and consent to participate**

The performed study was carried out using pseudonymized data. All procedures contributing to the work described comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

**Consent for publication**

Not applicable.
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

Not applicable.

Authors’ contributions

The study was designed by AP, HGMN and CvLB. Data analysis was performed by AP. Data interpretation was performed by AP. The manuscript was drafted by AP. The manuscript was revised by AP, MK, LG, ML, HGMN and CvLB. All authors read and approved the final manuscript.

Declaration of Competing Interest

The authors declare no conflicts of interests.

Acknowledgements

We would like to thank all technicians of the molecular section of the department of Medical Microbiology and Infection Control of the UMCG for excellent technical assistance.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jcv.2022.105326.

References

[1] World Health Organisation. WHO Coronavirus (COVID-19) Dashboard. http://covid19.who.int (accessed 23 August 2022).
[2] European Centre for Disease Prevention and Control. Assessment of the Further Spread and Potential Impact of the SARS-CoV-2 Omicron variant of Concern in the EU/EEA, 19th Update - 27 January 2022, Stockholm, ECDC, 2022.
[3] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019, N. Engl. J. Med. 382 (2020) 727–733.
[4] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506.
[5] European Centre for Disease Prevention and Control. Guidance on Ending the Isolation Period for People with COVID-19, Third update, 28 January 2022, ECDC, Stockholm, 2022.
[6] European Centre for Disease Prevention and Control. Guidance for COVID-19 Quarantine and Testing Options for travellers. 12 March 2021, ECDC, Stockholm, 2021.
[7] V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill. 25 (2020), 2000045, https://doi.org/10.2807/1560.
[8] S. Stanley, D.J. Hamel, I.D. Wolf, S. Riedel, S. Dutta, E. Contreras, et al., Limit of Detection for Rapid Antigen Testing of the SARS-CoV-2 Omicron and Delta Variants of Concern Using Live-Virus Culture, J. Clin. Microbiol. 60 (2022), e0014022, 22Epub 2022 Apr 20.
[9] L.W. Pray, L. Ford, D. Cole, C. Lee, J.P. Bigouette, G.R. Abedi, et al., Performance of an Antigen-Based Test for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University Campuses – Wisconsin, September-October 2020, MMWR Morb. Mortal. Wkly. Rep. 69 (2021) 1642–1647.
[10] M. Korenkov, N. Poopalasingam, M. Madler, K. Vanshylla, R. Eggeling, M. Wirtz, et al., Evaluation of a Rapid Antigen Test To Detect SARS-CoV-2 Infection and Identify Potentially Infectious Individuals, J. Clin. Microbiol. 59 (2021), e009621, 21Epub 2021 Aug 18.
[11] D.A. Mistry, J.Y. Wang, M.E. Moeser, T. Starkey, L.Y.W. Lee, A systematic review of the sensitivity and specificity of lateral flow devices in the detection of SARS-CoV-2, BMC Infect. Dis. 21 (2021), 828-021.
[12] L. Gard, M.A. Fliss, F. Bosma, D. Ter Veen, H.G.M Niesters, Validation and verification of the GeneFinder™ COVID-19 Plus Rapid Antigen Test on the ELITE InGenius® instrument, J. Virol. Methods 300 (2022), 114376.
[13] C. Bengtsson, M. Lopez, M. Esteban, P. Martin, P. Ramos, M.D. Cazorpa, et al., Viral culture and immunofluorescence for the detection of SARS-CoV-2 infectivity in RT-PCR positive respiratory samples, J. Clin. Virol. 152 (2022), 105167.
[14] S. Al Bayat, J. Mundodan, S. Hafnain, M. Sallam, H. Khogali, D. Ali, et al., Can the cycle threshold (Ct) value of RT-PCR test for SARS CoV2 predict infectivity among close contacts? J. Infect. Public Health 14 (2021) 1201–1205.
[15] B. La Scola, M. Le Bideau, J. Andreani, V.T. Hoang, C. Grimaldier, P. Colson, et al., Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards, Eur. J. Clin. Microbiol. Infect. Dis. 39 (2020) 1059–1061.
[16] S. Hird, R. Kubota-Koketsu, T. Sanaki, S. Morikawa, K. Motomura, E.E. Nakayama, et al., Infectivity assay for detection of SARS-CoV-2 in samples from patients with COVID-19, J. Med. Virol. 93 (2021) 5917–5923.
[17] J.J. Bayart, J. Degosserie, J. Favresse, C. Gigot, M. Didembourg, H.P. Djokoto, et al., Analytical Sensitivity of Six SARS-CoV-2 Rapid Antigen Tests for Omicron versus Delta Variant,Viruses 14 (2022) 654, https://doi.org/10.3390/v14040654.
[18] O. Donono Mantke, V.M. Corman, F. Taddei, E. McCulloch, D. Niemeyer, L. Grumiro, et al., Importance of external quality assessment for SARS-CoV-2 antigen detection during the COVID-19 pandemic, J. Clin. Virol. 154 (2022), 105222.
[19] P.S. Schneider, L. Molina, M.C. Picot, N. L’Helgoualch, J. Espeut, P. Champignieux, et al., Performances of rapid and connected salivary RT-LAMP diagnostic test for SARS-CoV-2 infection in ambulatory screening, Sci. Rep. 12 (2022), 2843-022.
[20] R. Pu, S. Liu, X. Ren, D. Shi, Y. Ba, Y. Huo, et al., The screening value of RT-LAMP assay for SARS-CoV-2 infection: cross sectional study, BMJ 374 (2021) n1676.
[21] A. Ptasinska, C. Whalley, A. Bosworth, C. Poxon, C. Bryer, N. Machin, et al., Diagnostic accuracy of loop-mediated isothermal amplification coupled to nanopore sequencing (LamPORE) for the detection of SARS-CoV-2 infection at scale in asymptomatic and symptomatic populations, Clin. Microbiol. Infect. 27 (2021), 1348.e1,1348.e7.
[22] J.L. Bayart, J. Degoserie, J. Favresse, C. Gillot, M. Didembourg, H.P. Djokoto, et al., Point-of-Care Antigen Test for SARS-CoV-2 in Asymptomatic Students, Emerg. Infect. Dis. 27 (2021) 2662–2665.
[23] A. Hunter, et al., Rapid Antigen Test for SARS-CoV-2 in Asymptomatic University Students, Emerg. Infect. Dis. 27 (2021) 2662–2665.